WuXi AppTec Co., Ltd. (HKG: 2359)

Market Cap	159.08B
Revenue (ttm)	42.65B
Net Income (ttm)	8.93B
Shares Out	n/a
EPS (ttm)	3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 17, 2024

Volume	2,160,472
Open	50.25
Previous Close	50.25
Day's Range	48.70 - 50.25
52-Week Range	27.50 - 95.35
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 41,116
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2023, WuXi AppTec's revenue was 40.34 billion, an increase of 2.51% compared to the previous year's 39.35 billion. Earnings were 9.61 billion, an increase of 9.00%.

Financial numbers in CNY